Period:
Draw Mode:
| Volume | 4,462,583 |
|
|||||
| News | - | ||||||
| Day High | 9.80 | Low High |
|||||
| Day Low | 9.57 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Viatris Inc | VTRS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.22 | 2.33% | 9.66 | 12:33:08 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 9.57 | 9.57 | 9.80 | 9.44 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 19,163 | 4,462,583 | $ 9.69 | $ 43,232,947 | - | 8.42 - 12.3993 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:33:08 | 100 | $ 9.66 | USD |
Viatris Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 11.56B | 1.20B | 1.06B | $ 16.26B | $ 2.11B | 1.71 | 5.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ 0.48 | 5.09% | 03/08/23 | - | 0.30% |
Viatris News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VTRS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 10.00 | 10.02 | 9.23 | 9.52 | 11,351,400 | -0.34 | -3.4% |
| 1 Month | 11.61 | 11.80 | 9.23 | 10.56 | 10,344,484 | -1.95 | -16.8% |
| 3 Months | 11.03 | 12.3993 | 9.23 | 11.29 | 9,378,417 | -1.37 | -12.42% |
| 6 Months | 9.19 | 12.3993 | 8.42 | 10.71 | 9,475,264 | 0.47 | 5.11% |
| 1 Year | 10.58 | 12.3993 | 8.42 | 10.59 | 10,531,293 | -0.92 | -8.7% |
| 3 Years | 16.46 | 18.86 | 8.42 | 12.84 | 10,481,775 | -6.80 | -41.31% |
| 5 Years | 16.46 | 18.86 | 8.42 | 12.84 | 10,481,775 | -6.80 | -41.31% |
Viatris Description
| Viatris Inc is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone). |